Regeneron adds $270 million to BARDA Ebola treatment supply contract through 2031
Regeneron Pharmaceuticals announced an extension of its agreement with the Biomedical Advanced Research and Development Authority (BARDA) to provide additional doses of its FDA‑approved Ebola therapy Inmazeb. The amendment adds roughly $270 million in value to the original 2020 procurement deal and extends deliveries to the U.S. government through 2031. The company also said it is advancing maftivimab, a component of Inmazeb, in a WHO‑sponsored trial for Bundibugyo virus in the DRC.
Why it matters
The extension will generate about $270 million in payments to Regeneron, bolstering its government‑contract revenue stream. It also secures a continued supply of Inmazeb for U.S. emergency stockpiles, supporting the company's role in Ebola preparedness.
Key facts
- 1The BARDA agreement was expanded by approximately $270 million in value. investing.com
- 2Regeneron will deliver additional Inmazeb doses to the U.S. government through 2031. investing.com
- 3The original procurement contract with BARDA began in 2020. grafa.com
- 4Inmazeb reduced mortality by about 55 % in clinical trials. investing.com
- 5Regeneron is adding investigational maftivimab to the PARTNERS trial for Bundibugyo virus disease. grafa.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.